EGFR and non-small cell lung carcinoma: TheFLAURA study showed that the use of triple TKI axitinib in the first-line treatmentof advanced EGFR mutated NSCLC can achieve longer PFS and OS (24), andclinical guidelines have been approved as a Class IA evidence level 1recommendation and included in health insurance reimbursement (25).